Entrada Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $526.3 Mil.
During the past 12 months, Entrada Therapeutics's average Total Assets Growth Rate was -9.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 93.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 156.10% per year.
During the past 6 years, Entrada Therapeutics's highest 3-Year average Total Assets Growth Rate was 256.80%. The lowest was 93.10%. And the median was 196.80%.
The historical data trend for Entrada Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Entrada Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (NAS:TRDA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Entrada Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Entrada Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Entrada Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRDA has been successfully added to your 